Pancreatic enzymes
Executive Summary
FDA's Gastrointestinal Drugs Advisory Committee will discuss reports of intestinal stricture occurring in cystic fibrosis patients taking high lipase activity pancreatic enzymes at its Feb. 17 meeting. The committee will consider what studies are needed to assess pancreatic enzyme safety. The meeting begins at 9 a.m. at the Holiday Inn in Bethesda, Md